

NEWS RELEASE

The Merck Healthcare Business Standardizes on Veeva CRM Globally to Improve Commercial Execution Across Channels

4/4/2019

Expansion in EMEA follows the business' success with Veeva CRM throughout North America, Latin America, and Asia Pacific

BARCELONA, Spain--(BUSINESS WIRE)-- **Veeva Systems** (NYSE:VEEV) today announced that the Healthcare business of **Merck** has selected **Veeva CRM** to improve operating efficiency and commercial effectiveness in Europe, Middle East, and Africa (EMEA). Building on the multi-year partnership with Veeva and following its success throughout North America, Latin America, and Asia Pacific, the business is now standardizing on **multichannel Veeva CRM** globally.

In addition to core Veeva CRM, the Healthcare business of Merck is expanding use of **Veeva CLM**, **Veeva CRM Approved Email**, and **Veeva CRM MyInsights** across the world. These solutions will enable the business to deliver a seamless customer experience across all channels, including face-to-face, email, and web.

"Understanding our customers and delivering them the right information at the right time through the right channel is key to our commercial strategy," said Chetak Buaria, global head of commercial excellence of the Healthcare business at Merck. "We are unifying on a single global CRM solution to deliver on this vision with Veeva as our trusted global partner."

"Veeva is committed to helping life sciences companies drive effective engagement with healthcare professionals," said Paul Shawah, senior vice president of **Veeva Commercial Cloud**. "We are proud to team with the Healthcare business of Merck on their important mission to bring innovative medicines to market."

Additional Information

For more on Veeva Vault CRM Suite, visit: veeva.com/eu/CRM-suite

Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems

Follow @veeva_eu on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems

About Veeva Systems

Veeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 700 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com/eu.

About Merck

Merck, a leading science and technology company, operates across healthcare, life science and performance materials. Around 52,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2018, Merck generated sales of € 14.8 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck's technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials.

Forward-looking Statements

This release contains forward-looking statements, including the market demand for and acceptance of Veeva's products and services, the results from use of Veeva's products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva's historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva's expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future.

These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva's financial results are included under the captions, "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations," in the company's filing on Form 10-K for the period ended January 31, 2019. This is available on the company's website at **veeva.com** under the Investors section and on the SEC's website at **sec.gov**. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190404005327/en/

Roger Villareal

Veeva Systems

925-264-8885

roger.villareal@veeva.com

Kiran May Veeva Systems

+44-796-643-2912

kiran.may@veeva.com

Source: Veeva Systems Inc.

3